{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:47Z","timestamp":1777289087724,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It may offer improved efficacy versus intravenous (IV) infliximab formulations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A network meta-regression was conducted using individual patient data from two randomised trials in patients with RA, which compared CT-P13 SC with CT-P13 IV, and CT-P13 IV with reference infliximab IV. In this analysis, CT-P13 SC was compared with CT-P13 IV, reference infliximab IV and pooled data for both reference infliximab IV and CT-P13 IV. Outcomes included changes from baseline in 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP), Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI), and rates of remission, low disease activity or clinically meaningful improvement in functional disability per Health Assessment Questionnaire\u2013Disability Index (HAQ-DI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The two studies enrolled 949 patients with RA; pooled data for 840 and 751 patients were evaluable at weeks 30 and 54, respectively. For the CT-P13 SC versus pooled IV treatment arm comparison, differences in changes from baseline in DAS28-CRP (\u2212\u20090.578; 95% confidence interval [CI] \u2212\u20090.831, \u2212\u20090.325; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), CDAI (\u2212\u20093.502; 95% CI \u2212\u20095.715, \u2212\u20091.289; <jats:italic>p<\/jats:italic>\u2009=\u20090.002) and SDAI (\u2212\u20094.031; 95% CI \u2212\u20096.385, \u2212\u20091.677; <jats:italic>p<\/jats:italic>\u2009=\u20090.0008) scores at 30\u2009weeks were statistically significant in favour of CT-P13 SC. From weeks 30 to 54, the magnitude of the differences increased and remained statistically significant in favour of CT-P13 SC. Similar results were observed for the comparison of CT-P13 SC with CT-P13 IV and with reference infliximab IV. Statistically significant differences at week 30 favoured CT-P13 SC over the pooled IV treatment arms for the proportions of patients achieving EULAR-CRP good response, American College of Rheumatology (ACR) 50 and ACR70 responses, DAS28-CRP-defined remission, low disease activity (DAS28-CRP, CDAI and SDAI criteria) and clinically meaningful HAQ-DI improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CT-P13 SC was associated with greater improvements in DAS28-CRP, CDAI and SDAI scores and higher rates of clinical response, low disease activity and clinically meaningful improvement in functional disability, compared with CT-P13 IV and reference infliximab IV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2016-002125-11\">2016-002125-11<\/jats:ext-link>, registered 1 July 2016; EudraCT <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2010-018646-31\">2010-018646-31<\/jats:ext-link>, registered 23 June 2010.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02487-x","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T06:05:00Z","timestamp":1618553100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Bernard","family":"Combe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taek Sang","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwon","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gahee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-4008","authenticated-orcid":false,"given":"Dae Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"issue":"11","key":"2487_CR1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","volume":"78","author":"S Safiri","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463\u201371. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215920.","journal-title":"Ann Rheum Dis"},{"key":"2487_CR2","doi-asserted-by":"publisher","first-page":"18002","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18002.","journal-title":"Nat Rev Dis Primers"},{"key":"2487_CR3","unstructured":"Centers for Disease Control and Prevention. Rheumatoid arthritis (RA). Available from: https:\/\/www.cdc.gov\/arthritis\/basics\/rheumatoid-arthritis.html. [cited 2021 January 29]."},{"issue":"10055","key":"2487_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8.","journal-title":"Lancet."},{"issue":"1","key":"2487_CR5","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1\u2013ITC16. https:\/\/doi.org\/10.7326\/AITC201901010.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2487_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.10731","volume":"48","author":"T Sokka","year":"2003","unstructured":"Sokka T, Krishnan E, H\u00e4kkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum. 2003;48(1):59\u201363. https:\/\/doi.org\/10.1002\/art.10731.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2487_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10067-004-0976-6","volume":"24","author":"E West","year":"2005","unstructured":"West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol. 2005;24(2):117\u201322. https:\/\/doi.org\/10.1007\/s10067-004-0976-6.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2487_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard.2003.019034","volume":"64","author":"K Puolakka","year":"2005","unstructured":"Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Hakala M, Korpela M, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis. 2005;64(1):130\u20133. https:\/\/doi.org\/10.1136\/ard.2003.019034.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2487_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2487_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524.","journal-title":"Ann Rheum Dis"},{"issue":"9194","key":"2487_CR11","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932\u20139.","journal-title":"Lancet"},{"issue":"5","key":"2487_CR12","first-page":"847","volume":"33","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J Rheumatol. 2006;33(5):847\u201353.","journal-title":"J Rheumatol"},{"key":"2487_CR13","unstructured":"European Medicines Agency. Remsima summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf. [cited 2021 January 29]."},{"key":"2487_CR14","unstructured":"US Food and Drug Administration. Highlights of prescribing information, inflectra (infliximab-dyyb). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s008lbl.pdf. [cited 2021 January 29]."},{"key":"2487_CR15","unstructured":"European Medicines Agency. Assessment report on extension(s) of marketing authorisation: Remsima. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/remsima-h-c-2576-x-0062-epar-assessment-report-variation_en.pdf. [cited 2021 January 29]."},{"key":"2487_CR16","doi-asserted-by":"publisher","unstructured":"Westhovens R, Wiland P, Zawadzki M, Ivanova D, Berrocal Kasay A, Chalouhi El-Khouri E et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. . Rheumatology (Oxford). 2020;doi: https:\/\/doi.org\/10.1093\/rheumatology\/keaa580 [epub ahead of print].","DOI":"10.1093\/rheumatology\/keaa580"},{"issue":"10","key":"2487_CR17","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203090.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2487_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18(1):82. https:\/\/doi.org\/10.1186\/s13075-016-0981-6.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2487_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, Van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl 39","key":"2487_CR20","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2487_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/art.30129","volume":"63","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573\u201386. https:\/\/doi.org\/10.1002\/art.30129.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2487_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64(5):640\u20137. https:\/\/doi.org\/10.1002\/acr.21649.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2487_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin N Am. 2009;35(4):745\u201357, vii-viii. https:\/\/doi.org\/10.1016\/j.rdc.2009.10.001.","journal-title":"Rheum Dis Clin N Am"},{"issue":"6","key":"2487_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729\u201340. https:\/\/doi.org\/10.1002\/art.1780360601.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2487_CR25","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","volume":"41","author":"DT Felson","year":"1998","unstructured":"Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41(9):1564\u201370. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2487_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41927-019-0095-2","volume":"3","author":"F Behrens","year":"2019","unstructured":"Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Gnann H, Greger G, et al. Use of a \u201ccritical difference\u201d statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3(1):51. https:\/\/doi.org\/10.1186\/s41927-019-0095-2.","journal-title":"BMC Rheumatol"},{"issue":"7","key":"2487_CR27","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","volume":"43","author":"M Kosinski","year":"2000","unstructured":"Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43(7):1478\u201387. https:\/\/doi.org\/10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M.","journal-title":"Arthritis Rheum"},{"issue":"16","key":"2487_CR28","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.2787","volume":"26","author":"O Harel","year":"2007","unstructured":"Harel O, Zhou X-H. Multiple imputation: review of theory, implementation and software. Stat Med. 2007;26(16):3057\u201377. https:\/\/doi.org\/10.1002\/sim.2787.","journal-title":"Stat Med"},{"key":"2487_CR29","unstructured":"Phillippo D, Ades AE, Dias S, Palmer S, K.R. A, Welton NJ. NICE DSU technical support document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. Available from: http:\/\/nicedsu.org.uk\/technical-support-documents\/population-adjusted-indirect-comparisons-maic-and-stc\/. [cited 2021 January 29]."},{"issue":"3","key":"2487_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/rssa.12579","volume":"183","author":"DM Phillippo","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE, Belger M, Brnabic A, Schacht A, et al. Multilevel network meta-regression for population-adjusted treatment comparisons. J R Stat Soc A Stat. 2020;183(3):1189\u2013210. https:\/\/doi.org\/10.1111\/rssa.12579.","journal-title":"J R Stat Soc A Stat"},{"key":"2487_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons Inc.; 1987. https:\/\/doi.org\/10.1002\/9780470316696."},{"issue":"5 Suppl 39","key":"2487_CR32","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2487_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429\u201337. https:\/\/doi.org\/10.1016\/j.jval.2011.01.011.","journal-title":"Value Health"},{"issue":"9","key":"2487_CR34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2006.065995","volume":"66","author":"MU Rahman","year":"2007","unstructured":"Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233\u20138. https:\/\/doi.org\/10.1136\/ard.2006.065995.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2487_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/ard.2004.030452","volume":"64","author":"GJ Wolbink","year":"2005","unstructured":"Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704\u20137. https:\/\/doi.org\/10.1136\/ard.2004.030452.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2487_CR36","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.10302","volume":"46","author":"EW St Clair","year":"2002","unstructured":"St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(6):1451\u20139. https:\/\/doi.org\/10.1002\/art.10302.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2487_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","volume":"19","author":"T Takeuchi","year":"2009","unstructured":"Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478\u201387. https:\/\/doi.org\/10.3109\/s10165-009-0195-8.","journal-title":"Mod Rheumatol"},{"issue":"22","key":"2487_CR38","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594\u2013602. https:\/\/doi.org\/10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"issue":"2","key":"2487_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/ard.2005.038513","volume":"65","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis. 2006;65(2):227\u201333. https:\/\/doi.org\/10.1136\/ard.2005.038513.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2487_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheumatism. 2005;52(1):27\u201335.","journal-title":"Arthritis Rheumatism"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02487-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02487-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02487-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T06:06:05Z","timestamp":1618553165000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02487-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2487"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02487-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"29 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BC received honoraria from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche-Chugai, Sanofi and UCB; and research grants from Novartis, Pfizer and Roche. YA declares no competing interests. RA received honoraria from AbbVie, Bristol-Myers Squibb, Celltrion, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche-Chugai and UCB; and research grants from Novartis, Pfizer and Roche. RC received a speaker\u2019s fee and a consultation grant from AbbVie, BMS, Celltrion, Fresenius-Kabi, Gilead-Galapagos, Lilly, MSD, Pfizer, Roche, Samsung-Bioepis, Sanofi and UCB. PD received speaker\u2019s fees from AbbVie, Bristol-Myers Squibb, Galapagos, Lilly and Sanofi<b>.<\/b> FI received a speaker\u2019s fee and consultation grant from AbbVie, Actelion, BMS, Biogen, Lilly, MSD, Pfizer, Roche, Sanofi and UCB. MTN received consulting fees from AbbVie, Celgene, Celltrion, Eli Lilly, Janssen and Sanofi; speakers fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Roche and Sanofi; and research funding from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, MSD, Mundipharma, Novartis, Pfizer, Roche and Sanofi. MT is a consultant at Creativ-Ceutical, an international consulting firm providing services to public and private organisations. Creativ-Ceutical provides services for most pharmaceutical industry companies including Celltrion. SJL is a full-time employee of Celltrion Inc. TSK is a full-time employee of Celltrion Healthcare. JN is a full-time employee of Celltrion Healthcare. GP is a full-time employee of Celltrion Inc. DHY is on the speaker\u2019s bureau for Celltrion and Celltrion Healthcare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}